학술논문
412O - A global phase II study of olmutinib (HM61713) in patients with T790M-positive NSCLC after failure of first-line EGFR-TKI
Document Type
Abstract
Author
Source
In Annals of Oncology November 2017 28 Supplement 10:x124-x124
Subject
Language
ISSN
0923-7534